申请人:Kura Oncology, Inc.
公开号:US10752639B2
公开(公告)日:2020-08-25
The present disclosure provides compounds of Formula (I-E) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
本公开提供了式 (I-E) 的化合物,用于抑制 menin 与 MLL1、MLL2 和 MLL 融合肿瘤蛋白的相互作用。这些化合物可用于治疗白血病、实体癌、糖尿病和其他依赖于 MLL1、MLL2、MLL 融合蛋白和/或 menin 活性的疾病。